What is recombinant zoster vaccine (RZV) (Shingrix)?

Updated: May 18, 2020
  • Author: Richard Lichenstein, MD; Chief Editor: Michael Stuart Bronze, MD  more...
  • Print


Zoster vaccine recombinant, adjuvanted (Shingrix)

  • Used for the prevention of herpes zoster (shingles) in patients aged 50 years or older; not used for the treatment of herpes zoster
  • Used in immunocompetent adults who previously received Zostavax
  • ACIP recommends new two-dose (Shingrix) preferentially over older one-dose (Zostavax)
  • Administer 0.5 mL (entire vial contents) IM in the deltoid region, 2-6 months apart

Approval was based on a multicenter trial, Zoster Efficacy Study in Adults 50 Years of Age or Older (ZOE-50). The trial was conducted in 18 countries in 13,900 people aged 70 years or older. Participants were randomized in a 1:1 ratio to receive either Shingrix or placebo. Mean follow-up period was 3.7 years. The efficacy for the prevention of herpes zoster was 96.6% in persons aged 50-59 years, 97.4% in persons aged 60-69 years, and 91.3% in persons aged 70 years or older. [5, 6]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!